Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 12/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4630497 | 0.97 | BCHE (0.47) | BCHEACHENPC1LPAR1LPAR5 | |
| SCHEMBL4630721 | 0.93 | BCHE (0.54) | BCHEACHELPAR1 | |
| SCHEMBL4630739 | 0.89 | LTB4R2 (0.52) | BCHENPC1LPAR1 | |
| SCHEMBL4630671 | 0.87 | LTB4R2 (0.55) | BCHELPAR1 | |
| Tert-Butylamine SCHEMBL5311587 | 0.85 | LTB4R2 (0.48) | BCHELPAR1 | |
| SCHEMBL4629851 | 0.85 | BCHE (0.56) | BCHEACHE | |
| SCHEMBL4631046 | 0.85 | PPARG (0.42) | ACHE | |
| Amantadine SCHEMBL5313147 | 0.84 | BCHE (0.46) | BCHEACHENPC1LPAR1 | |
| SCHEMBL4631519 | 0.81 | BCHE (0.57) | BCHEACHE | |
| Amantadine SCHEMBL5314966 | 0.81 | LTB4R2 (0.43) | BCHENPC1LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517883-B8 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2008-05-21 | — | — | EP | disclosed |
| US-7355069-B2 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| EP-1517883-B1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | EP | disclosed |
| US-20050256198-A1 | Ortho-substituted benzoic acid derivatives for the treatmetn of insulin resistance | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1517883-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | AstraZeneca AB (SE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000790-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256198-A1 | Ortho-substituted benzoic acid derivatives for the treatmetn of insulin resistance | GPR119, INSR, IRS1 | BCHE 2365/4885ACHE 4063/4885NPC1 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.